ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/NSW/2500-Wollongong-Wollongong-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
51
trial(s) found.
NCT06868199
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours (
LM168-01-101
)
anti-PD-1 monoclonal antibody
unknown drug class
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06792695
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (
CANTOR
)
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Volrustomig
anti-VEGF monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGF-targeting
therapeutic modality,bispecific antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06751329
Advanced
Phase 1
Recruiting
A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors (
DM002001
)
Colorectal cancer
Endometrial cancer
Ovarian cancer
Prostate cancer
NSW
2500 - Wollongong - Wollongong Hospital
NCT06669247
Haem
Phase 1 / Phase 2
Recruiting
A First-in-Human (FIH) Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN7945, an Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma (
R7945-ONC-22110
)
bispecific CD38/CD28 antibody
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4217 - Benowa - Pindara Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06656390
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors (
ALK201-01
)
anti-FGFR2b antibody-drug conjugate
Cancer
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
NCT06630806
Haem
Phase 1
Recruiting
A First-in-human, Open-label, Phase 1 Study to Evaluate the Safety, Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SAR446523, an Anti-GPRC5D ADCC-enhanced Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma (
TED18162
)
anti-GPRC5D monoclonal antibody
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT06613009
Advanced
Phase 1
Recruiting
A Phase 1 Multicenter, Open-label Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer (
CIBI3009A101
)
anti-DLL3 antibody-drug conjugate
Small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT06608927
Advanced
Phase 3
Recruiting
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma (
PRISM-1
)
CD73 inhibitor
placebo
Pancreatic adenocarcinoma
NSW
2500 - Wollongong - Wollongong Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06520345
Advanced
Phase 3
Recruiting
A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment (
177Lu-TLX591-203
)
177Lu-anti-PSMA-radioconjugate
Castrate-resistant prostate cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3051 - Melbourne - Australian Prostate Centre
WA
6150 - Murdoch - GenesisCare Murdoch
NCT06508658
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (
EPCORE-DLBCL-4
)
anti-CD20 monoclonal antibody
antimetabolite
bispecific T-cell engager,CD20-targeting
immunomodulatory imide drug
platinum-based antineoplastic agent
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4350 - Toowoomba - Toowoomba Hospital
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT06508489
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/Phase 2, Randomized, Open-label, Multi Cohort, Multi Center, Study Assessing the Safety, Tolerability and Preliminary Efficacy of SAR443579 a Natural Killer Cell Engager (NKCE) Targeting CD123, Administered With Different Agents in Participants With CD123 Expressing Hematological Malignancies (
TCD17796
)
NKp46-based NK-cell engager
Acute myeloid leukaemia
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06441747
Advanced
Phase 2
Recruiting
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (
BIL-PPP
)
PARP inhibitor
anti-PD-L1 monoclonal antibody
Cholangiocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06349408
Advanced
Phase 1
Recruiting
A Phase 1 Study of IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors (
CIBI3001A101
)
anti-EGFR/B7H3 antibody-drug conjugate
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06305962
Advanced
Phase 1
Recruiting
Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Solid Tumours (
177Lu-RAD204.2023.0001
)
radioconjugate,PD-L1-targeting
Cutaneous melanoma
Endometrial cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
QLD
4215 - Southport - Gold Coast University Hospital
4509 - North Lakes - Icon Cancer Centre North Lakes
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - GenesisCare Murdoch
NCT06233942
Advanced
Phase 1
Recruiting
Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors (
BG-C9074-101
)
anti-B7H4 antibody-drug conjugate
anti-PD-1 monoclonal antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT06211036
Advanced
Phase 3
Recruiting
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (
DeLLphi-305
)
anti-PD-L1 monoclonal antibody
bispecific T-cell engager,DLL3-targeting
topoisomerase inhibitor
Small-cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06208150
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide (
MonumenTAL-6
)
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6005 - West Perth - Perth Blood Institute
NCT06022029
Haem
Phase 1
Recruiting
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas (
ON-5001
)
anti-PD-1 monoclonal antibody
Bladder cancer
Cancer
Carcinoma
Cervical cancer
Diffuse large B-cell lymphoma
Follicular lymphoma
Head and neck squamous cell carcinoma
Lymphoma
Mantle cell lymphoma
Skin cancer
Triple-negative breast cancer
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Tasman Oncology
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05991349
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of IBI129 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors (
CIBI129A101
)
anti-B7H3 antibody-drug conjugate
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2217 - Kogarah - St George Private Hospital
2500 - Wollongong - Wollongong Hospital
NCT05952557
Curative
Phase 3
Recruiting
CAMBRIA-2
: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
selective estrogen receptor degrader
selective estrogen receptor modulator
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2500 - Wollongong - Wollongong Hospital
2576 - Bowral - Southern Highlands Cancer Centre
ACT
2605 - Garran - The Canberra Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3630 - Shepparton - Goulburn Valley Health
3677 - Wangaratta - Northeast Health Wangaratta
3844 - Traralgon - Latrobe Regional Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT05800015
Advanced
Phase 2 / Phase 3
Recruiting
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels (
R3767-ONC-2236
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05785767
Advanced
Phase 2 / Phase 3
Recruiting
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50% (
R3767-ONC-2235
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
2650 - Wagga Wagga - Riverina Cancer Care Centre
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
NCT05642780
Advanced
Phase 2
Recruiting
A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors (
SKB264-II-06
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT05555732
Advanced
Phase 3
Recruiting
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (
DS1062-A-U303
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
Non-squamous non-small-cell lung cancer
NSW
2217 - Kogarah - St George Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT05552222
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy (
MajesTEC-7
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05519085
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-1
cereblon E3 ligase modulator
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.9016 - Dunedin - Dunedin Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (WITHDRAWN)
NCT05462236
Advanced
Phase 2
Recruiting
A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer (
AUM001-2001-MK3475-D65
)
MNK1/2 inhibitor
anti-PD-1 monoclonal antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4217 - Benowa - Pindara Private Hospital
NCT05458219
Advanced
Phase 1
Recruiting
A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors (
CIBI343A101
)
anti-CLDN18.2 antibody-drug conjugate
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
NCT05325866
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (
FORTITUDE-301
)
anti-FGFR2b monoclonal antibody
Solid tumour
NSW
2031 - Randwick - Prince of Wales Hospital
2170 - Liverpool - Liverpool Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (TERMINATED)
QLD
4350 - Toowoomba - Toowoomba Hospital (TERMINATED)
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05317416
Haem
Phase 3
Recruiting
A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION (
MagnetisMM-7
)
bispecific T-cell engager,BCMA-targeting
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3066 - Epping - Northern Hospital
3121 - Richmond - Epworth Freemasons Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4217 - Benowa - Pindara Private Hospital
NCT04789096
Advanced
Phase 2
Recruiting
A Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients with Pre-treated Advanced HER2-positive Breast Cancer (
TUGETHER
)
ERBB2 inhibitor,third generation
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
Breast cancer
HER2-positive breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT04643002
Haem
Phase 1 / Phase 2
Recruiting
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol (
ACT16482
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
NCT04613596
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (
CA239-0009
)
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3168 - Clayton - Monash Medical Centre (WITHDRAWN)
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT04534205
Advanced
Phase 2 / Phase 3
Recruiting
An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (
AHEAD-MERIT
)
anti-PD-1 monoclonal antibody
vaccine therapy,HPV-E6/HPV-E7-targeting
Head and neck cancer
Head and neck squamous cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2500 - Wollongong - Wollongong Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital (WITHDRAWN)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (WITHDRAWN)
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT02889874
Curative
NA
Recruiting
A Randomised Phase III Trial of Adjuvant Radiation Therapy Versus Observation Following Breast Conserving Surgery and Endocrine Therapy in Patients With Molecularly Characterised Luminal A Early Breast Cancer (
EXPERT
)
radiotherapy
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2060 - North Sydney - Mater Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3002 - East Melbourne - Epworth Freemasons
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3135 - Ringwood East - Maroondah Hospital
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus
3199 - Frankston - GenesisCare Radiation Oncology Centre Frankston
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3353 - Ballarat - Ballarat Austin Radiation Oncology Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3844 - Traralgon - Latrobe Regional Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
4670 - Bundaberg - Bundaberg Hospital
SA
5037 - Glandore - GenesisCare Tennyson
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
ACTRN12623001077651
Advanced
Phase 1 / Phase 2
Recruiting
A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies - Module 2. (
EMITT-1
)
ERAP1 inhibitor
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
ACTRN12621000639820
Advanced
Phase 2
Recruiting
The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (
PARAGON-II
) .
Alpelisib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Letrozole
PI3K alpha inhibitor
Ribociclib
aromatase inhibitor
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,PI3Kalpha-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
oestrogen receptor-targeting therapy
Carcinoma
Endometrial cancer
Endometrial stromal sarcoma
Low-grade serous ovarian cancer
Ovarian cancer
Ovarian granulosa cell tumour
Platinum resistant high-grade epithelial cancers of fallopian tube
Platinum resistant ovarian cancer
Primary fallopian tube serous carcinoma
Uterine leiomyosarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2485 - Tweed Heads - The Tweed Hospital
2500 - Wollongong - Wollongong Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12620001198910
Advanced
Phase 2
Recruiting
Phase 2 Study of a Moderately Hypofractionated Schedule of Chemoradiation followed by Immunotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (
MODERN-LUNG
)
Carboplatin
Durvalumab
Paclitaxel
Radiotherapy
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
platinum-based antineoplastic agent
taxane
Lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
ACTRN12619000566134
Advanced
Phase 2
Recruiting
OXTOX
: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study
PDE4 inhibitor
platinum-based antineoplastic agent
Colorectal cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
2640 - Albury - Border Medical Oncology Research Unit
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
NCT06094140
Curative
Phase 2
Active not recruiting
NEO-adjuvant Chemo-Immunotherapy in Pancreatic Cancer (
NEO-IMPACT
)
Durvalumab
Filgrastim
Fluorouracil
Gemcitabine
Irinotecan
Leucovorin
Oxaliplatin
Pegfilgrastim
anti-PD-L1 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
Pancreatic cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3030 - Heidelberg - Ballarat Austin Radiation Oncology Centre
NCT05839626
Haem
Phase 1 / Phase 2
Active not recruiting
First-in-human, Open-label Phase 1/2 Study to Investigate Safety and Efficacy of SAR445514, an NKcell Engager (NKCE) Targeting B-cell Maturation Antigen (BCMA) in Monotherapy in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and in Relapsed/Refractory Light-chain Amyloidosis (RRLCA) (
TCD17710
)
BCMA-targeting antibody-based NK cell engager
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
NCT05704049
Haem
Phase 2
Active not recruiting
A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) (
ACT17453
)
anti-CD38 monoclonal antibody
glucocorticoid
proteasome inhibitor
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT05669989
Haem
Phase 2
Active not recruiting
International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study (
LTS17704
)
anti-CD38 monoclonal antibody
Multiple myeloma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05577715
Advanced
Phase 2
Terminated
A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (
CA116-003
)
anti-FR-alpha antibody-drug conjugate
Non-small cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05450692
Advanced
Phase 3
Active not recruiting
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy:
LATIFY
ATR inhibitor
anti-PD-L1 monoclonal antibody
taxane
Non-small cell lung cancer
NSW
2480 - Lismore - Lismore Base Hospital
2500 - Wollongong - Wollongong Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05405166
Haem
Phase 3
Active not recruiting
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (
IRAKLIA
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05311176
Advanced
Phase 2
Completed
NextHERIZON
: an Open-Label, Signal Generating, Phase 2 Study of HER-Vaxx in Combination with Chemotherapy or Pembrolizumab in Patients with Metastatic HER2/Neu Over-Expressing Gastric or Gastroesophageal Junction (GEJ) Adenocarcinomas Who Have Previously Received Trastuzumab and Progressed on This Treatment
ERBB2 B-cell antigen
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
NSW
2500 - Wollongong - Wollongong Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05306444
Advanced
Phase 1
Completed
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CLN-418 in Subjects With Advanced Solid Tumors (
CLN-418-001
)
bispecific B7H4/4-1BB antibody
Solid tumour
NSW
2217 - Kogarah - St George Hospital
2500 - Wollongong - Wollongong Hospital
NCT05297565
Curative
Phase 3
Completed
A Phase 3, Open Label, Randomized, Non-Inferiority Pharmacokinetic Study of Nivolumab Subcutaneous (Nivo SC) Versus Intravenous (Nivo IV) Administration in Participants With Stage IIIA/B/C/D or Stage IV Adjuvant Melanoma Following Complete Resection (
CheckMate-6GE
)
anti-PD-1 monoclonal antibody
Melanoma
NSW
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2500 - Wollongong - Wollongong Hospital
VIC
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
NCT04489368
Curative
Unknown
Pathological Response Prediction to Neo-adjuvant Chemoradiotherapy in Esophageal Carcinoma and Comparison of Engineered Features Versus Deep Learning Models (
QARC
)
Radiotherapy
cancer therapy
Oesophageal cancer
NSW
2500 - Wollongong - Wollongong Hospital
ACTRN12622000378729
Curative
Phase 2
Active not recruiting
Investigating the safety and efficacy of NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer,
NEO-IMPACT
.
Durvalumab
Filgrastim
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin
Pegfilgrastim
anti-PD-L1 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
Pancreatic cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (38)
Active not recruiting (7)
Completed (3)
Not yet recruiting (1)
Terminated (1)
Unknown (1)
Recruitment Country and State
NSW (51)
VIC (36)
QLD (25)
SA (19)
WA (18)
NZ (7)
ACT (4)
TAS (2)
Phase
Phase 1 (9)
Phase 1 / Phase 2 (9)
Phase 2 (14)
Phase 2 / Phase 3 (4)
Phase 3 (13)
Trial Type
Advanced (31)
Haem (14)
Curative (6)
Cancer Therapy Class
PD-1/PD-L1
43%
PD-1
29%
cereblon
16%
PD-L1
14%
CD38
12%
BCMA
8%
proteasome
8%
FGFR
4%
FGFR2
4%
FGFR2b
4%
DLL3
4%
B7H3
4%
B7H4
4%
GPRC5D
4%
CDK4
4%
CDK6
4%
oestrogen axis
4%
LAG3
4%
Trop2
4%
ERBB2
4%
CTLA4
2%
VEGF
2%
CD28
2%
CD73
2%
AR
2%
CYP17A1
2%
androgen axis
2%
CD20
2%
BCL2
2%
DNA methyltransferase
2%
PARP
2%
EGFR
2%
EGFR/B7H3
2%
CS1
2%
ER
2%
MNK
2%
CLDN18.2
2%
CD47
2%
ROCK2
2%
TGF-beta
2%
KRAS
2%
KRAS G12C
2%
HPV-E6
2%
HPV-E7
2%
ERAP1
2%
PI3Kalpha
2%
PDE4
2%
FR-alpha
2%
ATR
2%
VEGFR2
2%
4-1BB
2%
Facility
2500 - Wollongong - Wollongong Hospital (51)
3065 - Fitzroy - St Vincent's Hospital Melbourne (12)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (11)
2050 - Camperdown - Chris O'Brien Lifehouse (9)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (8)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (8)
2170 - Liverpool - Liverpool Hospital (8)
3168 - Clayton - Monash Medical Centre (7)
4102 - Woolloongabba - Princess Alexandra Hospital (7)
5042 - Bedford Park - Flinders Medical Centre (7)
3121 - Richmond - Epworth Freemasons Hospital (7)
6150 - Murdoch - Fiona Stanley Hospital (6)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (6)
3004 - Melbourne, Southbank - Alfred Health (5)
2109 - North Ryde - Macquarie University Hospital (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (5)
2031 - Randwick - Prince of Wales Hospital (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (5)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (5)
4217 - Benowa - Pindara Private Hospital (4)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (4)
2605 - Garran - The Canberra Hospital (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
3128 - Box Hill - Box Hill Hospital - Eastern Health (4)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (4)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (4)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (4)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (4)
4575 - Birtinya - Sunshine Coast University Hospital (3)
3002 - East Melbourne - Epworth Freemasons (3)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (3)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (3)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (3)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
6150 - Murdoch - GenesisCare Murdoch (2)
4350 - Toowoomba - Toowoomba Hospital (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
2200 - Bankstown - Bankstown-Lidcombe Hospital (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
3844 - Traralgon - Latrobe Regional Hospital (2)
NZ.3210 - Hamilton - Waikato Hospital (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
2217 - Kogarah - St George Hospital (2)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (2)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
3051 - Melbourne - Australian Prostate Centre (1)
6000 - Perth - Royal Perth Hospital (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
4509 - North Lakes - Icon Cancer Centre North Lakes (1)
6009 - Nedlands - Linear Clinical Research (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
6005 - West Perth - Perth Blood Institute (1)
4215 - Southport - Tasman Oncology (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2217 - Kogarah - St George Private Hospital (1)
2576 - Bowral - Southern Highlands Cancer Centre (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
3630 - Shepparton - Goulburn Valley Health (1)
3677 - Wangaratta - Northeast Health Wangaratta (1)
2650 - Wagga Wagga - Riverina Cancer Care Centre (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
3066 - Epping - Northern Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
2060 - North Sydney - Mater Hospital (1)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
3135 - Ringwood East - Maroondah Hospital (1)
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (1)
3199 - Frankston - GenesisCare Radiation Oncology Centre Frankston (1)
3353 - Ballarat - Ballarat Austin Radiation Oncology Centre (1)
4670 - Bundaberg - Bundaberg Hospital (1)
5037 - Glandore - GenesisCare Tennyson (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2485 - Tweed Heads - The Tweed Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
3030 - Heidelberg - Ballarat Austin Radiation Oncology Centre (1)
2480 - Lismore - Lismore Base Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Thoracic cancer
Multiple myeloma
Plasma cell disorder
Gastrointestinal cancer
Lung cancer
Respiratory tract cancer
Non-small cell lung cancer
Upper gastrointestinal cancer
Carcinoma
Breast cancer
Colorectal cancer
Lower gastrointestinal cancer
Gynaecological cancer
Pancreatobiliary cancer
Endometrial cancer
Urogenital cancer
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Pancreatic cancer
Breast adenocarcinoma
Head and neck cancer
Head and neck squamous cell carcinoma
Melanoma
Male genital cancers
Ovarian cancer
Prostate cancer
B-cell lymphoma
B-cell malignancy
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Skin cancer
Triple-negative breast cancer
Gastroesophageal cancer
Oesophageal cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Acute myeloid leukaemia
Leukaemia
Myeloid leukaemia
Biliary tract cancer
Cholangiocarcinoma
Hepatobiliary cancer
Cutaneous melanoma
Bladder cancer
Cervical cancer
Follicular lymphoma
HPV-related cancer
HPV16-positive cancer
Mantle cell lymphoma
Uveal melanoma
Viral-related cancer
Non-squamous non-small-cell lung cancer
HER2-positive breast cancer
Endometrial stromal sarcoma
Epithelial Ovarian Cancer
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Leiomyosarcoma
Low-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian granulosa cell tumour
Ovarian serous carcinoma
Platinum resistant high-grade epithelial cancers of fallopian tube
Platinum resistant ovarian cancer
Primary fallopian tube serous carcinoma
Sarcoma
Sex cord-gonadal stromal tumour
Soft tissue sarcoma
Uterine leiomyosarcoma
Gastric adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy